BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported strong fourth quarter 2015 financial results.
“We are pleased to report another quarter of strong financial performance reflecting continued positive momentum across our entire portfolio,” said Ludwig Hantson, chief executive officer and president, Baxalta.
